Vitiligo
☆ U rezultatima Stiftung Warentest iz Njemačke za 2022., zadovoljstvo potrošača s ModelDermom bilo je samo malo niže nego s plaćenim konzultacijama o telemedicini.
Vitiligo na prstima je teže liječiti nego na drugim područjima. Osim što je kozmetički ružan, vitiligo je normalan i nije zarazan. U dermatologiji je najučinkovitiji tretman fototerapija ili laserski tretman (excimer) 2-3 puta tjedno tijekom najmanje 1 godine. Ako ne možete često ići u bolnicu zbog financijskih razloga ili zbog posla, možete isprobati aparat za fototerapiju koji je odobren za kućnu upotrebu.
Vitiligo očnih kapaka
Vitiligo na ruci
References
Vitiligo je čest kožni poremećaj koji uzrokuje mrlje bijele kože zbog gubitka melanocita. Najnovija istraživanja pokazuju da je to autoimuna bolest. Iako se na to često gleda kao na kozmetički problem, može duboko utjecati na mentalno blagostanje i svakodnevni život. Godine 2011. Stručnjaci su klasificirali tip pod nazivom segmental vitiligo odvojeno od ostalih.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Pacijenti s aktivnim vitiligom imaju nekoliko mogućnosti terapije, kao što su sistemski glukokortikoidi, fototerapija i sistemski imunosupresivi. Stabilni pacijenti s vitiligom mogu pronaći olakšanje lokalnim kortikosteroidima, lokalnim inhibitorima kalcineurina, fototerapijom i postupcima transplantacije. Nedavni napredak u razumijevanju temeljnih procesa vitiliga doveo je do razvoja ciljanih terapija. Trenutačno, JAK inhibitori najviše obećavaju, nude dobru podnošljivost i funkcionalne ishode, unatoč riziku od aktiviranja latentnih infekcija i sistemskih nuspojava uobičajenih kod drugih imunosupresivnih lijekova. Istraživanje koje je u tijeku ima za cilj identificirati ključne citokine uključene u razvoj vitiliga (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Blokiranje ovih citokina pokazalo se obećavajućim u životinjskim modelima i nekim pacijentima. Osim toga, u tijeku su istrage protiv miRNA-based therapeutics i adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ne postoji poznati lijek za vitiligo. Za one sa svijetlom puti, krema za sunčanje i šminka su sve što se obično preporučuje. Druge mogućnosti liječenja mogu uključivati steroidne kreme ili fototerapiju.
○ liječenje
#Phototherapy
#Excimer laser
#Tacrolimus ointment